ABSTRACT
The health care-related infections are well-known in a critical care setting, but reports of those infections in solid organ transplanted patients are scarce. We developed a study of retrospective cohort in a tertiary teaching hospital for 14 months. Eighty-one patients underwent solid organ transplants. The global incidence of health care-related infection was 42.0 percent. Fifteen percent of the cases were occurrences of surgical site infections, 14.0 percent pneumonias, 9.0 percent primary blood stream infections, 4.0 percent urinary tract infections and 2.0 percent skin infection. The most prevalent etiologic agents were K. pneumoniae (8.6 percent), P. aeruginosa (7.4 percent); A. baumannii (5.0 percent) and S. aureus (2.5 percent). Mortality was 18.0 percent, none of then related to health care infections. The high rate of those infections, mainly surgical site infections, suggests a demand for stricter measures to prevent and control health care-related infections.
Subject(s)
Adult , Female , Humans , Male , Cross Infection/epidemiology , Gram-Negative Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/epidemiology , Organ Transplantation , Brazil/epidemiology , Cross Infection/microbiology , Epidemiologic Methods , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/microbiology , Hospitals, TeachingABSTRACT
The health care-related infections are well-known in a critical care setting, but reports of those infections in solid organ transplanted patients are scarce. We developed a study of retrospective cohort in a tertiary teaching hospital for 14 months. Eighty-one patients underwent solid organ transplants. The global incidence of health care-related infection was 42.0%. Fifteen percent of the cases were occurrences of surgical site infections, 14.0% pneumonias, 9.0% primary blood stream infections, 4.0% urinary tract infections and 2.0% skin infection. The most prevalent etiologic agents were K. pneumoniae (8.6%), P. aeruginosa (7.4%); A. baumannii (5.0%) and S. aureus (2.5%). Mortality was 18.0%, none of then related to health care infections. The high rate of those infections, mainly surgical site infections, suggests a demand for stricter measures to prevent and control health care-related infections.
Subject(s)
Cross Infection/epidemiology , Gram-Negative Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/epidemiology , Organ Transplantation , Adult , Brazil/epidemiology , Cross Infection/microbiology , Epidemiologic Methods , Female , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/microbiology , Hospitals, Teaching , Humans , MaleABSTRACT
In order to evaluate the clinical efficacy of Fludilat, we studied 75 patients, 37 women (49.3 per cent) and 38 men (50.7 per cent), with ages between 36 and 98 years, during a period of 3 months. 50 of the patients received Fludilat at the dose of three tablets per day during 3 months. The remaining 25 patients received Placebo during the same period of time. We obtained very good results in 63.5 per cent, good in 20.4 per cent and poor in 16.1 per cent of the patients treated with Fludilat. The results with Placebo were very good 2.9 per cent, good 41.8 per cent and poor 55.3 per cent. We observed no side effects during the treatment. Therefore from our study we conclude that Fludilat is an effective drug in the treatment of the disturbances produced by the cerebral vascular insufficiency.